TSX:ONC 0.70 CAD +0.03 +4.48% Volume: 337,772 August 27, 2015
NASDAQ:ONCY 0.53 USD +0.01 +2% Volume: 530,772 August 27, 2015

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

August 27, 2015 Oncolytics Biotech® Inc. Collaborators to Present Survival Data from REO 016 Study in Non-Small Cell Lung Cancer
August 26, 2015 Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Non-Small Cell Lung Cancer Study
August 12, 2015 MEDIA ADVISORY - Oncolytics Biotech® Inc. to Participate in the 35th Annual Canaccord Genuity Growth Conference
Sign up to receive e-mail updates *